CRBP
What one share of Corbus Pharmaceuticals Holdings holds
Pharmaceutical Preparations
Corbus Pharmaceuticals Holdings, Inc. (the “Company” or “Corbus”) is a clinical stage company focused on promising new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways.
Corbus Pharmaceuticals Holdings’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$6.09 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$5.18 |
| Cash and investments | $1.25 |
| Book value | $5.48 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2013 | — | −$2.70 | — | −$1.58 | — | −$7.68 |
| 2014 | — | −$3.90 | $0.10 | −$3.61 | — | $6.78 |
| 2015 | $0.62 | −$8.47 | $0.11 | −$4.53 | — | $7.17 |
| 2016 | $1.39 | −$14.58 | $0.26 | −$10.15 | — | $5.99 |
| 2017 | $1.46 | −$19.38 | $0.42 | −$17.04 | — | $31.18 |
| 2018 | $2.54 | −$29.30 | $1.21 | −$17.04 | — | $14.42 |
| 2019 | $16.97 | −$33.55 | $1.29 | −$22.75 | — | $2.86 |
| 2020 | $1.51 | −$42.72 | $0.19 | −$38.46 | — | $13.74 |
| 2021 | $0.22 | −$11.15 | $0.01 | −$11.78 | — | $16.57 |
| 2022 | $0.00 | −$10.15 | $0.00 | −$9.01 | — | $7.91 |
| 2023 | — | −$10.31 | $0.00 | −$8.34 | — | −$1.56 |
| 2024 | — | −$3.68 | $0.00 | −$3.83 | — | $11.69 |
| 2025 | — | −$5.90 | $0.00 | −$4.84 | — | $8.38 |